Uruguay's metaBIX Signs Global Licensing Deal With India's HiMedia, Projects $40M in Royalties

Inside metaBIX's Global Licensing Agreement With HiMedia

Uruguayan biotechnology startup metaBIX has signed a global licensing agreement with Mumbai-based HiMedia Laboratories, a deal founder and CEO Laura Macció says will open commercial access across all continents.

Founded in 2022, metaBIX has built a biovigilance platform combining biotechnology and artificial intelligence to anticipate disease outbreaks in animal production. Under the agreement, HiMedia will use metaBIX's data and know-how to develop its own products, and the startup will receive royalties on the resulting sales. No capital is being injected by either side, and the arrangement is scheduled to start in October. Because HiMedia products are sold in more than 150 countries, the licence has global rather than India-only reach.

The deal followed 18 months of work in India and about 20 pilots across the country's four regions. metaBIX previously raised more than $1 million from funds including AIR Capital and Danta Fund and had started expanding into Brazil and Mexico. Macció said the alliance could support a much larger product portfolio and estimated royalties could exceed $40 million over a seven-year horizon.

HiMedia was founded in Mumbai in 1976 and now controls about 80% of India's microbiological culture media market, according to Crisil Ratings, an S&P Global affiliate. It posted revenue of 1,040 crore rupees, approximately $120 million, in fiscal 2025, up 17% year on year. Exports accounted for about 24% of sales and grew 21%, helped by demand from Latin America, the Middle East and Russia. The relationship grew out of a US-based adviser found on LinkedIn and included four trips to India, a visit to Uruguay by an MIT-trained family executive, and parallel discussions about HiMedia's possible installation in Uruguay.

What the metaBIX–HiMedia Pact Changes for Both Companies

The Royalty Model Gives metaBIX Scale Without Upfront Capital

The structure is notable for a venture-backed startup: instead of selling software licences or taking equity from HiMedia, metaBIX will earn a share of sales from products HiMedia develops using its data and AI-generated insights. That gives the Uruguayan company exposure to HiMedia's distribution network across more than 150 countries without putting up capital. The $40 million figure, however, is a seven-year projection from the founder, not a disclosed contractual guarantee. For context, HiMedia's entire revenue in fiscal 2025 was about $120 million, so hitting that royalty total would require meaningful new product sales from the alliance.

HiMedia Is Buying a Faster Route Into Animal Health Data

HiMedia already controls roughly 80% of India's microbiological culture media market and is expanding beyond its core into probiotics, cultivated meat and 3D bioprinting. metaBIX's animal production biovigilance data and AI add a new product-building layer: rather than developing the underlying technology itself, HiMedia can use metaBIX's know-how to launch kits and diagnostics in its own commercial channels. That fits with HiMedia's export push, where sales grew 21% in the latest year, especially into Latin America, the Middle East and Russia.

Uruguay Becomes a Regional Staging Option

The commercial relationship has pulled Uruguay into HiMedia's expansion planning. HiMedia already operates in Latin America and exports to the region; Macció says the firm is evaluating Uruguay as a base to consolidate that presence. metaBIX's network of associated laboratories in Latin America, with particular strength in Brazil, is a complementary asset that could help HiMedia regionalize products and support. For Uruguay, the potential installation of a mid-sized Indian biotech company would add another node to a growing trade relationship, though no final decision is announced.

What Could Bend the $40 Million Projection

The most important caveat is that royalties are tied to actual product sales, not to signatures. The companies have not disclosed the specific number of products, the target markets, or any minimum milestones. Regulatory approval for animal-health or diagnostic products can vary considerably across the more than 150 countries HiMedia serves. The pact starts in October, but the first royalty-bearing sales could be years away. metaBIX is also choosing not to open an India office, relying on the partnership and advisers for commercial execution.

Next Moves for metaBIX, HiMedia and Their Investors

• For metaBIX leadership: Convert the founder's $40 million royalty estimate into contractual milestones early in the October launch — product categories, first market approvals, and sales thresholds — so the seven-year figure is testable rather than anecdotal.
• For metaBIX's early investors, including AIR Capital and Danta Fund: Judge the deal against HiMedia's actual export capacity, not the headline projection alone. HiMedia's exports were about 24% of a roughly $120 million revenue base in fiscal 2025, so royalty income will depend on how quickly co-developed products enter Latin America, the Middle East, and Russia.
• For HiMedia's regional team: Use metaBIX's Brazilian laboratory network to accelerate product validation in Latin America while the Uruguay base question is still being evaluated, because Brazil is already the region where HiMedia is gaining ground.
• For Uruguayan trade and biotech bodies: Treat HiMedia's interest in Uruguay as a live but unfinalized opportunity. The credible next step is to structure a specific installation proposal before the October agreement begins, since the companies are currently working on the strategy.